Brian Adams
CIK: 0001636994
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (17 total)
- Sep 4, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Direct3K shares at avg. $116.81$353K - Sep 4, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Direct2.1K shares at avg. $117.57$251K - Sep 4, 2026KYMR
Kymera Therapeutics, Inc.
Sale(S)Direct1.2K shares at avg. $115.55$140K - Mar 2, 2026KYMR
Kymera Therapeutics, Inc.
Award(A)Direct4.1K shares- - Sep 3, 2025KYMR
Kymera Therapeutics, Inc.
Award(A)Direct52.5K shares- - Jul 29, 2025RLAY
Relay Therapeutics, Inc.
Sale(S)Direct18.3K shares at avg. $3.68$67K - Jul 28, 2025RLAY
Relay Therapeutics, Inc.
Sale(S)Direct1.6K shares at avg. $3.74$6K - Apr 30, 2025RLAY
Relay Therapeutics, Inc.
Sale(S)Direct12.9K shares at avg. $3.00$39K - Apr 28, 2025RLAY
Relay Therapeutics, Inc.
Sale(S)Direct1.6K shares at avg. $3.17$5K - Mar 27, 2025RLAY
Relay Therapeutics, Inc.
Sale(S)Direct298 shares at avg. $2.84$846.32 - Jan 30, 2025RLAY
Relay Therapeutics, Inc.
Sale(S)Direct20.8K shares at avg. $4.42$92K - Jan 28, 2025RLAY
Relay Therapeutics, Inc.
Sale(S)Direct33.7K shares at avg. $4.63$156K - Jan 28, 2025RLAY
Relay Therapeutics, Inc.
Award(A)Direct139.1K shares- - Jan 10, 2025RLAY
Relay Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
275K shares- - Dec 27, 2024RLAY
Relay Therapeutics, Inc.
Sale(S)Direct299 shares at avg. $4.38$1K - Oct 28, 2024RLAY
Relay Therapeutics, Inc.
Sale(S)Direct1.6K shares at avg. $6.06$10K - Sep 27, 2024RLAY
Relay Therapeutics, Inc.
Sale(S)Direct295 shares at avg. $7.51$2K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 4, 2026 |  KYMR Kymera Therapeutics, Inc. | Sale(S) | 3,025 | $116.81 | $353,350 | Direct |
| Sep 4, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 2,137 | $117.57 | $251,247 | Direct |
| Sep 4, 2026 | KYMR Kymera Therapeutics, Inc. | Sale(S) | 1,209 | $115.55 | $139,700 | Direct |
| Mar 2, 2026 | KYMR Kymera Therapeutics, Inc. | Award(A) | 4,125 | - | $0 | Direct |
| Sep 3, 2025 | KYMR Kymera Therapeutics, Inc. | Award(A) | 52,500 | - | - | Direct |
| Jul 29, 2025 |  RLAY Relay Therapeutics, Inc. | Sale(S) | 18,276 | $3.68 | $67,256 | Direct |
| Jul 28, 2025 | RLAY Relay Therapeutics, Inc. | Sale(S) | 1,637 | $3.74 | $6,122 | Direct |
| Apr 30, 2025 | RLAY Relay Therapeutics, Inc. | Sale(S) | 12,943 | $3.00 | $38,829 | Direct |
| Apr 28, 2025 | RLAY Relay Therapeutics, Inc. | Sale(S) | 1,644 | $3.17 | $5,211 | Direct |
| Mar 27, 2025 | RLAY Relay Therapeutics, Inc. | Sale(S) | 298 | $2.84 | $846 | Direct |
| Jan 30, 2025 | RLAY Relay Therapeutics, Inc. | Sale(S) | 20,791 | $4.42 | $91,896 | Direct |
| Jan 28, 2025 | RLAY Relay Therapeutics, Inc. | Sale(S) | 33,688 | $4.63 | $155,975 | Direct |
| Jan 28, 2025 | RLAY Relay Therapeutics, Inc. | Award(A) | 139,141 | - | $0 | Direct |
| Jan 10, 2025 | RLAY Relay Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 275,000 | - | - | Direct |
| Dec 27, 2024 | RLAY Relay Therapeutics, Inc. | Sale(S) | 299 | $4.38 | $1,310 | Direct |
| Oct 28, 2024 | RLAY Relay Therapeutics, Inc. | Sale(S) | 1,632 | $6.06 | $9,890 | Direct |
| Sep 27, 2024 | RLAY Relay Therapeutics, Inc. | Sale(S) | 295 | $7.51 | $2,215 | Direct |
1-17 of 17 transactions
About Adams Brian
Adams Brian (SEC CIK 0001636994) files insider reports with the SEC as Chief Legal Officer of Kymera Therapeutics, Inc. (KYMR) and Chief Legal Officer of Relay Therapeutics, Inc. (RLAY).
Signal8 holds 12 ownership filings by Adams Brian (1 Form 3, 11 Form 4), filed between Oct 1, 2024 and Sep 4, 2026. Those filings report 17 transactions, from Sep 27, 2024 to Sep 4, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Adams Brian's filings is in WATERTOWN, MA.
Recent filings by Adams Brian
- Sep 4, 2026: Open-market sales of KYMR shares (3 lines, Form 4, code S).
- Mar 2, 2026: Grant or award of KYMR shares (Form 4, code A).
- Sep 3, 2025: Grant or award of KYMR shares (Form 4, code A).
- Jul 29, 2025: Open-market sale of RLAY shares (Form 4, code S).
- Jul 28, 2025: Open-market sale of RLAY shares (Form 4, code S).
Other insiders filing for Kymera Therapeutics, Inc. (KYMR)
- Mainolfi Nello, Chief Executive Officer
- Rooney Terence, Chief Medical Officer
- Jacobs Bruce N., Chief Financial Officer
- Goodman Noah, Chief Business Officer
- Booth Bruce, Director
- BVF PARTNERS L P/IL, Director